CD8A and neoplasm: In addition, hPSMA/4-1BB bsApt displayed reduced off-target (off-tumor) immune effects compared with anti-4-1BB mAb, as measured by decreased spleen, lymph node, and liver mass and lower CD8+ T cell populations (%).